Shanghai Novamab Biopharmaceuticals Co., Ltd.

4:15 PM - 4:30 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104C
Shanghai Novamab Biopharmaceuticals Co., Ltd is an innovative biopharmaceutical company dedicated to the development of novel nanobody drugs for patients all over the world. It was established in 2017, and now has more than 90 full time employees. Novamab is the first corporation in China that had a CMC process development platform of Pichia pastoris. Novamab has established the first platform for nanobody drug inhalation and delivery in China. In Sept. 2020, Novamab successfully passed the recognition of high-tech enterprises in Shanghai, becoming a "high-tech enterprise". Novamab has developed more than 10 nanobody drugs pipeline covering respiratory, anti-infection, ophthalmology and oncology. An inhalable candidate for asthma treatment was under clinical investigation both in Australia and China. Another nanobody drug for both Th2-low and Th2-high asthma and COPD has received clinical approval document.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Shanghai Novamab Biopharmaceuticals Co., Ltd.